Dr. Vinay Prasad Appointed as New Head of FDA's Center for Biologics Evaluation
Dr. Vinay Prasad's appointment as vaccine chief at the FDA raises concerns about future vaccine approvals, amid criticism of the agency's past policies.
COVID-19 booster critic tapped to lead FDA vaccine program
Washington Examiner
Overview
Dr. Vinay Prasad has been appointed head of the FDA's Center for Biologics Evaluation and Research, succeeding Dr. Peter Marks. Prasad, known for his controversial critiques of COVID-19 policies, has expressed skepticism about previous vaccine approvals, particularly for children. His appointment has raised investor concerns, with biotech stocks falling following the announcement. Kommissioner Dr. Marty Makary praised Prasad's scientific rigor, but public health experts worry that his views may hinder vaccine approvals. Marks resigned in March amid disagreements with HHS Secretary Robert F. Kennedy Jr. regarding transparency and vaccine safety.
Content generated by AI—learn more or report issue.
Get both sides in 5 minutes with our daily newsletter.
Analysis
- Dr. Vinay Prasad's appointment as head of the FDA's CBER is seen as a controversial move due to his history of criticism towards the FDA's handling of vaccine approvals, especially during the COVID-19 pandemic.
- Prasad's criticisms focus on the need for more rigorous clinical data before vaccine approvals, which may suggest an upcoming shift in FDA policies towards vaccines and biotech drugs.
- Prasad's previous statements about vaccines and the FDA raise concerns regarding the agency’s relationship with pharmaceutical companies and the regulation of new therapies.
Articles (9)
Center (4)
No highlight available for this article.
NBC News·2M·No highlight available for this article.
ARS Technica·2M·No highlight available for this article.
CBS News·2M·No highlight available for this article.
Associated Press·2M·FAQ
Dr. Vinay Prasad has criticized the FDA's approach to pharmaceutical approvals, including fast-tracked COVID boosters and other accelerated approvals, and has voiced skepticism about unproven cancer treatments and the agency's regulatory flexibility in supporting certain drug approvals. He has also expressed concerns about COVID-19 mandates and the lack of transparency during the pandemic.
Following the announcement of Dr. Vinay Prasad's appointment, biotech stocks fell. Analysts cited the appointment as contributing to regulatory uncertainty for the sector.
DrPeter Marks resigned after seeking to block Health Secretary Robert F. Kennedy Jr. from accessing vaccine safety databases, reportedly fearing that Kennedy's team might overwrite or erase the data. He was said to have been given a choice to resign or be fired in March.
CBER is responsible for the regulation of vaccines, blood products, gene therapies, and other biological products, ensuring their safety, efficacy, and quality for the public.
Public health experts worry that Dr. Prasad's critical views on vaccine approvals and COVID-19 mandates may lead to delays or increased scrutiny in the process of approving new vaccines, potentially affecting public health goals.
History
- 2M
3 articles